Healthcare & Pharma Marketing Agency | NUUN Digital

Quick answer

NUUN Digital's Healthcare & Pharma practice serves hospitals and health systems, pharmaceutical manufacturers, medical devices, digital health, and diagnostics with HCP and patient research, HIPAA and PIPEDA-compliant marketing, digital transformation, and AI builds. Every engagement is scoped with medical-legal-regulatory (MLR) review loops embedded from week one — not bolted on at launch.

HIPAA · PIPEDA · PHIPA

Privacy frameworks covered

ISO 20252

Research instruments compliant

MLR workflow

Review loops in every scope

12–18 mo

Typical pharma launch engagement

What healthcare & pharma clients hire us for

HCP research — quant and qual with specialty-specific panels (physicians, nurses, specialists). Patient research — ethnography, journey mapping, and VoC for condition-specific cohorts. Hospital system marketing — acquisition, access, and patient experience for health systems. Pharma launch support across market landscape, positioning, HCP engagement, and (where permitted) DTC. Digital transformation including EHR-adjacent software, patient portals, and AI-powered clinical workflow tools. AI builds — RAG-based clinical support tools where appropriate, intake and triage automation, pharmacovigilance analytics.

What's different about healthcare & pharma at NUUN

MLR review in the workflow. Every creative, landing page, and model ships through the client's Medical-Legal-Regulatory review process — we structure the workflow around MLR from intake, not at the tail end.

HIPAA, PIPEDA, and provincial health-privacy compliance. Data handling is architected for PHI rules week one. We've delivered under HIPAA, PIPEDA, Ontario PHIPA, Alberta HIA, and UK NHS data handling. Specialty-specific HCP panels — not "physicians," but "cardiologists treating heart failure," "oncologists specializing in breast cancer," or "nurses in acute care."

Named methods we apply in healthcare & pharma

HCP research with specialty-qualified panels and IRB-reviewable protocols where applicable. Patient ethnography and journey mapping for condition-specific cohorts. PHI-separated data architecture — PHI where it belongs, analytics where they need to be. Marketing mix modelling for hospital-system acquisition and patient access. MLR-embedded creative review loops. AI governance aligned to NIST AI RMF and ISO/IEC 42001 for every clinical-adjacent build.

Segments we work across

Hospitals and health systems · Pharmaceutical (small molecule and biologics) · Medical devices · Diagnostics · Digital health apps and platforms · Specialty pharmacy · Long-term care · Home healthcare · Health insurance payers · Clinical research organizations.

Selected work

Pharma client — HCP research + launch plan → launch exceeded volume forecast by [X]%. Read case →
Anonymized health system — Patient journey rebuild → time-to-first-visit reduced by [X] days. Read case →
Anonymized — digital health — HIPAA-compliant mobile app → [X]k active users in year one. Read case →

Sources & further reading

HHS — HIPAA for Business Associates (US HIPAA regulatory reference)
Office of the Privacy Commissioner of Canada — PIPEDA (Canadian privacy-regulation reference)
Health Canada (Canadian health regulator)
NIST AI Risk Management Framework (AI governance framework for clinical-adjacent builds)
ISO 20252 — market research quality standard (research-quality standard)

NUUN Digital Healthcare Practice — Head of Research, Health. HCP and patient research, HIPAA and PIPEDA-compliant data architecture, MLR-embedded marketing workflow, pharma launch and health-system growth.

Healthcare & Pharma FAQ.

Can you handle HIPAA-covered engagements?

Yes. We operate under Business Associate Agreements (BAAs) where required, maintain HIPAA-compliant data architectures, and separate PHI-handling environments from analytics environments. For Canadian clients, equivalent privacy frameworks (PIPEDA, PHIPA, HIA) apply.

Do you do DTC pharma marketing?

In jurisdictions where it's permitted (primarily US). Canadian pharma DTC is restricted under the Food and Drugs Act; we work within those restrictions with branded and disease-awareness campaign types. We decline work that doesn't fit the regulatory reality.

How do you handle HCP research panel recruitment?

Through audited partner panels specialized in HCP recruitment, with NUUN-led screening, instrument design, and quality control. We do not compromise on specialty qualification; mis-specified panels produce misleading data.

Can you support a pharma launch end-to-end?

Yes. A typical pharma launch engagement spans 12–18 months including landscape research, positioning, HCP engagement strategy, marketing architecture, and in-market tracking. Launch support is one of our highest-volume pharma engagement types.

Do you work with medical devices and diagnostics?

Yes. Medical devices and diagnostics share much of the pharma methodology (HCP research, compliant marketing, MLR review) with additional specificity around the device life cycle and reimbursement environment.

How do you approach AI in healthcare?

Conservatively and documented. Patient-facing AI requires extra scrutiny — we build with human-in-the-loop patterns, ship bias and drift monitoring, and write plain-language explainability docs a clinician or regulator can read. We decline autonomous-decision AI in clinical workflows.

Science-grade rigour, patient-grade care.